Fig. 1.
Fig 2.
Proteins and albumins values between the patient group and outcomes
| COVID-19 group (mean±SD) | H1N1 group (mean±SD) | Control group (mean±SD) | p* | Survivors (mean±SD) | Deceased (mean±SD) | p** | |
|---|---|---|---|---|---|---|---|
| BAL albumin (g/L) | 1.63±1.35 | 1.55±1.46 | 0.07±0.07 | <0.001 | 0.58±1.11 | 1.71±1.34 | <0.001 |
| BAL total protein (g/L) | 1.53±0.71 | 1.47±0.71 | 0.43±0.35 | <0.001 | 0.85±0.71 | 1.52±0.72 | <0.001 |
| Serum albumin (g/L) | 28.73±4.97 | 31.93±4.85 | 38.43±4.03 | <0.001 | 36.09±5.17 | 28.61±4.89 | <0.001 |
Demographic variables, days of invasive mechanical ventilation and outcome between two groups of ARDS patients
| COVID-19 group | H1N1 group | p* | Survivors | Deceased | p** | |
|---|---|---|---|---|---|---|
| Patients (n) | 30 | 14 | NA | 13 (29.5%) | 31(70.5%) | NA |
| Age (median, IQR) | 72.5 (35–83) | 62 (34–69) | <0.01 | 60 (35–70) | 72 (34–83) | <0.01 |
| Male (n,%) | 17 (56.7%) | 7(50%) | 0.7 | 9 (37.5%) | 15 (62.5%) | 0.24 |
| COPD (n,%) | 3 (10%) | 3 (21.4%) | 0.43 | 1 (16.7%) | 5 (83.3%) | 0.57 |
| CV diseases (n,%) | 18 (60%) | 6 (42.9%) | 0.33 | 6 (25%) | 18 (75%) | 0.51 |
| Diabetes (n,%) | 6 (20%) | 2 (14%) | 0.71 | 1 (12.5%) | 7 (87.5%) | 0.35 |
| CMV days (median, IQR) | 13 (1–31) | 14 (1–34) | 0.27 | 13 (1–39) | 13 (1–39) | 0.5 |
| Survivors (n,&) | 5 (16.7%) | 8 (57.1%) | <0.01 | NA | NA | NA |